Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
677.00    10.00 (1.50%)
Bid:
676.00
Ask:
678.00
Spread: 2.00 (0.296%)
Market Cap: £589.84m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM & Q1 Interim Management Statement

11 Feb 2022 07:00

RNS Number : 3658B
Victrex PLC
11 February 2022
Β 
Β 

Β 

11 February 2022

Victrex plc - AGM & Q1 Interim Management Statement

'Solid start to FY 2022; continuing momentum & healthy demand; FY expectations unchanged'

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's Interim Management Statement (IMS) covers the first quarter of our FY 2022 financial year from 1 October 2021 to 31 December 2021.

Β 

Overall, the Group saw a solid start to FY 2022 and for Q1 as a whole:

Β 

Β· Group revenue of Β£74.6m was 9% ahead of the prior year (Q1 2021: Β£68.7m)

Β· Q1 Group sales volume of 1,025 tonnes was 16% ahead of the prior year (Q1 2021: 883 tonnes)

Β· On a year-to-date (YTD) basis to 31 January 2022, Group volume and revenue is ahead of the prior year, with volume up double-digit.

Β 

End market performance

Across our end-markets, Electronics, Energy & Industrial, Medical and VAR saw good year year-on-year growth. Reflecting the current challenges in the Automotive industry, performance was modestly down year-on-year although it has improved from the final quarter of our FY 2021 financial year.

Β 

The strong performance in Medical included record quarterly revenues in Asia-Pacific. Medical revenues in the US were slightly lower as the impact of the Omicron variant impacted surgery rates in late 2021.

Mega-programmes

The Group retains an attractive portfolio of short, medium and long-term growth opportunities. In our Knee mega-programme, the clinical trial now has a total of 10 patients with implants, none requiring remedial intervention, with 8 patients having passed the 6-month clinical milestone stage. This success has led to the progression of options for additional partnerships and clinical studies.

Β 

In Trauma, with the In2Bones partnership established and commercial launches expected in the second half, subject to US FDA approval, we are preparing for the next phase of manufacturing scale-up, including partner opportunities in Asia.

Β 

Financial position & capital allocation

Victrex retains a highly cash generative business model, with available cash of Β£113.6m at 31 December 2021 (excluding cash ringfenced for our PVYX facility in China). Available cash is prior to payment of the 2021 final dividend and special dividend on 18th February 2022. FY 2022 is expected to be a year of high capital expenditure totalling approximately Β£60m, focused on China capacity, UK asset improvement and mega-programmes.

Β 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "This is a solid start to FY 2022, with continuing momentum and healthy top-line demand.

Β 

"Expectations for the full year are unchanged at this early stage. Whilst we anticipate further volume improvement across several end markets, we are mindful of headwinds including currency, raw material costs and increasing energy inflation. Overall, we continue on plan to deliver year-on-year growth in FY 2022.

"Our second and third quarters will see stronger comparators and as previously communicated, we do not expect to enjoy the restocking benefit seen in Value Added Resellers during the prior year. Our price recovery programme is progressing well, although additional recent increases in energy and raw material costs mean that progress on margin improvement may be held back, particularly in the second half.

"With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

Analyst & investor conference call

A conference call with management will take place this morning, Friday 11th February 2022, at 08.30am GMT via +44 (0) 3333 000804 and PIN 98055646#Β A replay of the call is also available at +44 (0) 333 300 0819 and PIN 425018338#

Β 

Annual General Meeting

Victrex's Annual General Meeting will also be held today, starting at 11.00am GMT and taking place at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP. Shareholders are asked to note JP Morgan protocols for attendance including:

Β 

a. taking a COVID-19 Lateral Flow Device test within 24 hours prior to attending the AGM and only attend if this is negative

b. wear a face mask or visor toΒ minimiseΒ risk of COVID-19 transmission

c. maintain social distancing guidance, or at least 1m distanceΒ between yourself and othersΒ 

d. use the sanitiser provided

e. Avoid shaking hands

Β 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

Β 

Β 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
QRFGPUCWPUPPPWU
Date   Source Headline
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
10th May 20231:34 pmRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSVictrex plc - Interim Results 2023
28th Apr 20239:33 amRNSTotal Voting Rights
18th Apr 20232:00 pmRNSHolding(s) in Company
18th Apr 202310:50 amRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSDirectorate Change
31st Mar 202310:52 amRNSTotal Voting Rights
20th Mar 20233:07 pmRNSHolding(s) in Company
20th Mar 202310:15 amRNSDirector/PDMR Shareholding
13th Mar 202310:14 amRNSAdditional Listing
28th Feb 20239:35 amRNSTotal Voting Rights
17th Feb 202310:06 amRNSDirector/PDMR Shareholding
14th Feb 202312:20 pmRNSDirector/PDMR Shareholding
10th Feb 20232:12 pmRNSDirector/PDMR Shareholding
10th Feb 202312:29 pmRNSResult of AGM
10th Feb 20237:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202310:43 amRNSTotal Voting Rights
17th Jan 20232:12 pmRNSDirector/PDMR Shareholding
12th Jan 20232:28 pmRNSCorrection - AGM Resolution Proposal
6th Jan 20232:58 pmRNSAnnual Report and Accounts
30th Dec 20229:00 amRNSTotal Voting Rights
22nd Dec 202211:30 amRNSDirector/PDMR Shareholding
19th Dec 202212:04 pmRNSDirector/PDMR Shareholding
19th Dec 202210:56 amRNSDirector/PDMR Shareholding
13th Dec 202211:16 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSVictrex plc – Preliminary Results 2022
1st Dec 202211:49 amRNSBlock listing Interim Review
30th Nov 20229:27 amRNSTotal Voting Rights
29th Nov 20224:05 pmRNSHolding(s) in Company
17th Nov 20222:50 pmRNSDirector/PDMR Shareholding
17th Nov 20221:35 pmRNSAdditional Listing
31st Oct 202212:55 pmRNSTotal Voting Rights
18th Oct 202212:26 pmRNSDirector/PDMR Shareholding
30th Sep 202211:03 amRNSTotal Voting Rights
28th Sep 20229:44 amRNSHolding(s) in Company
20th Sep 20224:05 pmRNSDirector/PDMR Shareholding
31st Aug 20229:00 amRNSTotal Voting Rights
17th Aug 20222:31 pmRNSDirector/PDMR Shareholding
29th Jul 202210:01 amRNSTotal Voting Rights
19th Jul 20222:41 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202210:28 amRNSTotal Voting Rights
21st Jun 202212:41 pmRNSDirector/PDMR Shareholding
7th Jun 202211:45 amRNSBlock listing Interim Review
31st May 20229:59 amRNSTotal Voting Rights
27th May 20229:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.